ScreenerHero

MDWD MediWound Ltd.

NAS · US · Healthcare · Biotechnology · mediwound.com
12.85USD-2.28%Mkt Cap: 165.90M $P/E: —

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap165.90M USD
Enterprise Value143.03M USD
Revenue (TTM)11.86M USD
Gross Profit3.25M USD
Net Income (TTM)-23.88M USD
Revenue/Share0.96 USD
Last Price12.85 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees121
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.74
PEG—
EV/EBITDA-4.65
EV/Revenue12.06
P/S14.31
P/B4.76
EPS (TTM)-2.17
EPS (Forward)-2.29
52W Range
12.524% of range20.03
52W High20.03 USD
52W Low12.52 USD
Profitability
Gross Margin19.19%
Oper. Margin-305.89%
EBITDA Margin-259.20%
Profit Margin-140.80%
ROE-54.73%
ROA-27.68%
Growth
Revenue Growth-45.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.12M USD
CapEx (TTM)5.50M USD
FCF Margin-244.87%
FCF Yield-17.51%
Net Debt-26.74M USD
Net Debt/EBITDA0.87
Balance Sheet
Debt/Equity0.19
Current Ratio2.32
Quick Ratio2.09
Book Value/Sh2.76 USD
Cash/Share2.74 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:7
Split DateDec 20, 2022
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)30.67 USD
Upside (mean)+138.7%
Target Range25.00 USD – 36.00 USD
25.00+138.7% to mean36.00
# Analysts6
Ownership
Shares Out.12.91M
Float8.87M
Insiders16.71%
Institutions55.88%
Short Interest
Short Ratio15.0d
Short % Float16.04%
Short % Out.14.05%
Shares Short1.81M
Short (prev mo.)1.59M
Technical
SMA 5013.60 (-5.5%)
SMA 20015.80 (-18.7%)
Beta0.09
S&P 52W Chg15.78%
Avg Vol (30d)96.33K
Avg Vol (10d)63.76K
Technical Indicators
RSI (14)37.3
MACD-0.0846
MACD Signal-0.0224
MACD Hist.-0.0622
BB Upper14.18 USD
BB Middle13.58 USD
BB Lower12.97 USD
BB Width8.91%
ATR (14)0.4549 USD
Vol Ratio (20d)0.80x